European Research Initiative on CLL

ERIC | Publications

Publications

Sutton LA, Hadzidimitriou A, Baliakas P, Agathangelidis A, Langerak AW, Stilgenbauer S, Pospisilova S, Davis Z, Forconi F, Davi F, Ghia P, Rosenquist R, Stamatopoulos K, European Research Initiative on CLL (ERIC).

Immunoglobulin genes in chronic lymphocytic leukemia: key to understanding the disease and improving risk stratification.

Rosenquist R, Ghia P, Hadzidimitriou A, Sutton LA, Agathangelidis A, Baliakas P, Darzentas N, Giudicelli V, Lefranc M, Langerak A, Belessi C, Davi F, Stamatopoulos K.

Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: updated ERIC recommendations

Rosenquist R, Rosenwald A, Du MQ, Gaidano G, Groenen P, Wotherspoon A, Ghia P, Gaulard P, Campo E, Stamatopoulos K; European Research Initiative on CLL (ERIC) and the European Association for Haematopathology (EAHP).

Clinical impact of recurrently mutated genes on lymphoma diagnostics: state-of-the-art and beyond

..............................................................................................................................................................................................................................................................................................

Sutton LA, Young E, Baliakas P, Hadzidimitriou A, Moysiadis T, Plevova K, Rossi D, Kminkova J, Stalika E, Pedersen LB, Malcikova J, Agathangelidis A, Davis Z, Mansouri L, Scarfò L, Boudjoghra M, Navarro A, Muggen AF, Yan XJ, Nguyen-Khac F, Larrayoz M, Panagiotidis P, Chiorazzi N, Niemann CU, Belessi C, Campo E, Strefford JC, Langerak AW, Oscier D, Gaidano G, Pospisilova S, Davi F, Ghia P, Stamatopoulos K, Rosenquist R; ERIC, the European Research Initiative on CLL.

Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors

........................................................................................................................................................................

Montserrat E, Dreger P.

Treatment of Chronic Lymphocytic Leukemia With del(17p)/TP53 Mutation: Allogeneic Hematopoietic Stem Cell Transplantation or BCR-Signaling Inhibitors?

...................................................................................................................................................................................

Dreger P, Montserrat E

Transplantation in CLL: what we can learn from a dinosaur

...............................................................................................................................................................................................................................................................................................................

Dowling AK, Liptrot SD, O'Brien D, Vandenberghe E.

Optimization and Validation of an 8-Color Single-Tube Assay for the Sensitive Detection of Minimal Residual Disease in B-Cell Chronic Lymphocytic Leukemia Detected via Flow Cytometry.

........................................................................................................................................................................

Rawstron AC, Fazi C, Agathangelidis A, Villamor N, Letestu R, Nomdedeu J, Palacio C, Stehlikova O, Kreuzer KA, Liptrot S, O'Brien D, de Tute RM, Marinov I, Hauwel M, Spacek M, Dobber J, Kater AP, Gambell P, Soosapilla A, Lozanski G, Brachtl G, Lin K, Boysen J, Hanson C, Jorgensen JL, Stetler-Stevenson M, Yuan C, Broome HE, Rassenti L, Craig F, Delgado J, Moreno C, Bosch F, Egle A, Doubek M, Pospisilova S, Mulligan S, Westerman D, Sanders CM, Emerson R, Robins HS, Kirsch I, Shanafelt T, Pettitt A, Kipps TJ, Wierda WG, Cymbalista F, Hallek M, Hillmen P, Montserrat E, Ghia P

A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia (CLL): An European research initiative on CLL study.

....................................................................................................................................................................

Pospisilova S, Sutton LA, Malcikova J, Tausch E, Rossi D, Montserrat E, Moreno C, Stamatopoulos K, Gaidano G, Rosenquist R, Ghia P, on behalf of the European Research Initiative on CLL (ERIC)

Innovation in the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go?

............................................................................................................................................................................................................................................................

Bystry V, Agathangelidis A, Bikos V, Sutton LA, Baliakas P, Hadzidimitriou A, Stamatopoulos K, Darzentas N; European Research Initiative on CLL (ERIC)

ARResT/AssignSubsets: a novel application for robust subclassification of chronic lymphocytic leukemia based on B cell receptor IG stereotypy

........................................................................................................................................................................

Montserrat E, Dreger P

Hope for high-risk chronic lymphocytic leukemia relapsing after allogeneic stem-cell transplantation

.......................................................................................................................................................................................................................................................................................................

Moreno C, Montillo M, Panayiotidis P, Dimou M, Bloor A, Dupuis J, Schuh A, Norin S, Geisler C, Hillmen P, Doubek M, Trněný M, Obrtlikova P, Laurenti L, Stilgenbauer S, Smolej L, Ghia P, Cymbalista F, Jaeger U, Stamatopoulos K, Stavroyianni N, Carrington P, Zouabi H, Leblond V, Gomez-Garcia JC, Rubio M, Marasca R, Musuraca G, Rigacci L, Farina L, Paolini R, Pospisilova S, Kimby E, Bradley C, Montserrat E

Ofatumumab In Poor-Prognosis Chronic Lymphocytic Leukemia: A Phase IV, Non-Interventional, Observational Study From The European Research Initiative On Chronic Lymphocytic Leukemia

..................................................................................................................................................................................................................................................................................................................................................................................................................

Baliakas P, Hadzidimitriou A, Sutton LA, Rossi D, Minga E, Villamor N, Larrayoz M, Kminkova J, Agathangelidis A, Davis Z, Tausch E, Stalika E, Kantorova B, Mansouri L, Scarfò L, Cortese D, Navrkalova V, Rose-Zerilli MJ, Smedby KE, Juliusson G, Anagnostopoulos A, Makris AM, Navarro A, Delgado J, Oscier D, Belessi C, Stilgenbauer S, Ghia P, Pospisilova S, Gaidano G, Campo E, Strefford JC, Stamatopoulos K, Rosenquist R; European Research Initiative on CLL (ERIC).

Recurrent mutations refine prognosis in chronic lymphocytic leukemia

..................................................................................................................................................................................................................................................................................................................................................................................................................

Dreger P, Montserrat E; European Society for Blood and Marrow Transplantation (EBMT); European Research Initiative on CLL (ERIC). Curr Hematol Malig Rep. 2015 Mar;10(1):59-64. doi: 10.1007/s11899-014-0242-1. Review.

Abstract

Where Does Allogeneic Stem Cell Transplantation fit in the Treatment of Chronic Lymphocytic Leukemia?

..................................................................................................................................................................................................................................................................................................................................................................................................................

Dreger P, Schetelig J, Andersen N, Corradini P, van Gelder M, Gribben J, Kimby E, Michallet M, Moreno C, Stilgenbauer S, Montserrat E, European Research Initiative on CLL (ERIC) and the European Society for Blood and Marrow Transplantation (EBMT).

Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?

..................................................................................................................................................................................................................................................................................................................................................................................................................

Te Raa GD, Malčiková J, Mraz M, Trbusek M, Le Garff-Tavernier M, Merle-Béral H, Greil R, Merkel O, Pospíšilová S, Lin K, Pettitt AR, Stankovic T, van Oers MH, Eldering E, Stilgenbauer S, Zenz T, Kater AP; European Research Initiative on CLL (ERIC).

Assessment of TP53 functionality in chronic lymphocytic leukaemia by different assays; an ERIC-wide approach

.......................................................................................................................................................................................................................................................................................

Benner A, Mansouri L, Rossi D, Majid A, Willander K, Parker A, Bond G, Pavlova S, Nückel H, Merkel O, Ghia P, Montserrat E, Kaderi MA, Rosenquist R, Gaidano G, Dyer MJ, Söderkvist P, Linderholm M, Oscier D, Tvaruzkova Z, Pospisilova S, Dührsen U, Greil R, Döhner H, Stilgenbauer S, Zenz T; European Research Initiative on CLL (ERIC).

MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis

..................................................................................................................................................................................................................................................................................................................................................................................................................

Te Raa GD, Malcikova J, Pospisilova S, Trbusek M, Mraz M, Garff-Tavernier ML, Merle-Béral H, Lin K, Pettitt AR, Merkel O, Stankovic T, van Oers MH, Eldering E, Stilgenbauer S, Zenz T, Kater AP; European Research Initiative on CLL (ERIC)

Overview of available p53 function tests in relation to TP53 and ATM gene alterations and chemoresistance in chronic lymphocytic leukemia

..................................................................................................................................................................................................................................................................................................................................................................................................................

Rawstron AC, Böttcher S, Letestu R, Villamor N, Fazi C, Kartsios H, de Tute RM, Shingles J, Ritgen M, Moreno C, Lin K, Pettitt AR, Kneba M, Montserrat E, Cymbalista F, Hallek M, Hillmen P, Ghia P

Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL

..................................................................................................................................................................................................................................................................................................................................................................................................................

Pospisilova S, Gonzalez D, Malcikova J, Trbusek M, Rossi D, Kater AP, Cymbalista F, Eichhorst B, Hallek M, Döhner H, Hillmen P, van Oers M, Gribben J, Ghia P, Montserrat E, Stilgenbauer S, Zenz T, European Research Initiative on CLL (ERIC).

ERIC recommendations on TP53 mutation analysis in Chronic Lymphocytic Leukemia

........................................................................................................................................................................

Durrieu F, Geneviève F, Arnoulet C, Brumpt C, Capiod JC, Degenne M, Feuillard J, Garand R, Kara-Terki A, Kulhein E, Maynadié M, Ochoa-Noguera ME, Plesa A, Roussel M, Eghbali H, Truchan-Graczyk M, de Carvalho Bittencourt M, Feugier P, Béné MC.

Normal levels of peripheral CD19(+) CD5(+) CLL-like cells: toward a defined threshold for CLL follow-up -- a GEIL-GOELAMS study

...................................................................................................................................................................................................................

Langerak AW, Davi F, Ghia P, Hadzidimitriou A, Murray F, Potter KN, Rosenquist R, Stamatopoulos K, Belessi C, European Research Initiative on CLL (ERIC).

Immunoglobulin sequence analysis and prognostication in CLL: guidelines from the ERIC review board for reliable interpretation of problematic cases

..................................................................................................................................................................................................................................................................................................................................................................................................................

Zenz T, Vollmer D, Trbusek M, Smardova J, Benner A, Soussi T, Helfrich H, Heuberger M, Hoth P, Fuge M, Denzel T, Häbe S, Malcikova J, Kuglik P, Truong S, Patten N, Wu L, Oscier D, Ibbotson R, Gardiner A, Tracy I, Lin K, Pettitt A, Pospisilova S, Mayer J, Hallek M, Döhner H, Stilgenbauer S; European Research Initiative on CLL (ERIC).

TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations

........................................................................................................................................................................

........................................................................................................................................................................

Zenz T, Mertens D, Küppers R, Döhner H, Stilgenbauer S.

From pathogenesis to treatment of chronic lymphocytic leukaemia

..................................................................................................................................................................................................................................................................................................................................................................................................................

Kostas Stamatopoulos, Paolo Ghia, Richard Rosenquist, Eds.

New Biological prognostic markers in CLL

WKHealth Books| 2010 ISBN: 978-88-7556-551-0

prognosticmarkerscover
This book is free to ERIC members!

..................................................................................................................................................................................................................................................................................................................................................................................................................

Michael Keating, Emili Montserrat, Eds.


Updates in chronic lymphocytic leukemia

Permanyer Publications | 2009 ISBN: 978-84-92620-25-8

updates-in-CLL_2009_cover_thumb
This book is free to ERIC members!

..................................................................................................................................................................................................................................................................................................................................................................................................................


Zenz T, Mohr J, Eldering E, Kater AP, Bühler A, Kienle D, Winkler D, Dürig J, van Oers MH, Mertens D, Döhner H, Stilgenbauer S.

miR-34a as part of the resistance network in chronic lymphocytic leukemia

..................................................................................................................................................................................................................................................................................................................................................................................................................

Zenz T, Mohr J, Edelmann J, Sarno A, Hoth P, Heuberger M, Helfrich H, Mertens D, Dohner H, Stilgenbauer S

Treatment resistance in chronic lymphocytic leukemia: the role of the p53 pathway.

..................................................................................................................................................................................................................................................................................................................................................................................................................

Paolo Ghia, Richard Rosenquist, Frederic Davì, Eds.


Immunoglobulin gene analysis in Chronic Lymphocytic Leukemia


WKHealth Books | 2008 ISBN: 978-88-7556-377-6

ig_analysis_book_cover_thumb
This book is free to ERIC members!

..................................................................................................................................................................................................................................................................................................................................................................................................................

Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) updating the National Cancer Institute-Working Group NCI-WG) 1996 guidelines

..................................................................................................................................................................................................................................................................................................................................................................................................................

Rawstron AC, Villamor N, Ritgen M, Böttcher S, Ghia P, Zehnder JL, Lozanski G, Colomer D, Moreno C, Geuna M, Evans PA, Natkunam Y, Coutre SE, Avery ED, Rassenti LZ, Kipps TJ, Caligaris-Cappio F, Kneba M, Byrd JC, Hallek MJ, Montserrat E, Hillmen P on behalf of European Research Initiative on CLL (ERIC) and the CLL Research Consortium (http://cll.ucsd.edu/)

International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia

........................................................................................................................................................................

Letestu R, Rawstron A, Ghia P, Villamor N, Boeckx N, Boettcher S, Buhl AM, Duerig J, Ibbotson R, Kroeber A, Langerak A, Le Garff-Tavernier M, Mockridge I, Morilla A, Padmore R, Rassenti L, Ritgen M, Shehata M, Smolewski P, Staib P, Ticchioni M, Walker C, Ajchenbaum-Cymbalista F, and On behalf of the ERIC (European Research Initiative in CLL) and the Leukemianet

Evaluation of ZAP-70 expression by flow cytometry in chronic lymphocytic leukemia: A multicentric international harmonization process

Este sitio web ha sido creado y es gestionado mediante la tecnología uniweb, desarrollada por intelligenia.

Web - Ingeniería y Diseño - intelligenia
Contact